Advertisement
Advertisement
HROW
Harrow, Inc. Common Stock
38.23
USDSponsored
-0.82
-2.10%
May 08, 16:00 UTC -4
Closed
Pre-Market
38.79
+0.56
+1.45%
HROW Earnings Reports
Positive Surprise Ratio
HROW beat 12 of 33 last estimates.
36%
Next Report
Today AMC
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$53.47M
/-$0.40
Implied change from Q4 25 (Revenue/ EPS)
-39.98%
/-335.29%
Implied change from Q1 25 (Revenue/ EPS)
+11.79%
/-20.00%
Harrow, Inc. Common Stock earnings per share and revenue
On Mar 02, 2026, HROW reported earnings of 0.17 USD per share (EPS) for Q4 25, missing the estimate of 0.37 USD, resulting in a -54.80% surprise. Revenue reached 89.09 million, compared to an expected 90.22 million, with a -1.25% difference. The market reacted with a -27.96% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 8 analysts forecast an EPS of -0.40 USD, with revenue projected to reach 53.47 million USD, implying an decrease of -335.29% EPS, and decrease of -39.98% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.33
Actual
-$0.37
Surprise
-9.82%
Collegium Pharmaceutical, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
$1.62
Actual
$1.76
Surprise
+8.43%
4D Molecular Therapeutics, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.01
Actual
-$1.01
Surprise
+0.21%
Akebia Therapeutics, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.02
Actual
-$0.03
Surprise
-4.90%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.37
Surprise
-17.01%
OmniAb, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.10
Actual
-$0.06
Surprise
+41.18%
Stevanato Group S.p.A.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.10
Actual
$0.11
Surprise
+5.45%
Crinetics Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.26
Actual
-$1.23
Surprise
+2.51%
Nektar Therapeutics
Report Date
May 07, 2026 For Q1 26
Estimate
-$1.62
Actual
-$1.82
Surprise
-11.88%
Definium Therapeutics, Inc. Common Shares
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.50
Actual
-$0.71
Surprise
-41.43%
FAQ
What were Harrow, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Harrow, Inc. Common Stock reported EPS of $0.17, missing estimates by -54.8%, and revenue of $89.09M, -1.25% below expectations.
How did the market react to Harrow, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -27.96%, changed from $53.59 before the earnings release to $38.60 the day after.
When is Harrow, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Harrow, Inc. Common Stock's next earnings report?
Based on 8
analysts, Harrow, Inc. Common Stock is expected to report EPS of -$0.40 and revenue of $53.47M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement